Rep’s shotgun request misfires
October 28, 2010Sales and Marketing ABPI Code of Practice, PMCPCA, Sanofi-Aventis
Sanofi-Aventis has been found in breach of the ABPI Code over the conduct of one of its representatives in relation …
GSK makes record whistleblower payout
October 28, 2010Manufacturing and Production Cheryl Eckard, FDA, GSK, GlaxoSmithKline, manufacturing compliance, whistle blower
GlaxoSmithKline has officially agreed to plead guilty to distributing adulterated drugs made at its now-closed facility in Cidra, Puerto Rico, …
Engaging the digital audience
October 28, 2010Medical Communications Andy Bell, Huntsworth Health, Jon Clark, Talking Point, digital marketing, digital pharma
We live in exciting times. With the rise of social media, people are changing the way they consume information. As …
NICE refuses cancer drugs Arzerra, Torisel and Levact
October 27, 2010Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs
NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …
Intercell appoints Staph Leavenworth Bakali
October 27, 2010Research and Development Intercell, Staph Leavenworth Bakali, appointment, research and development
Austrian biotech company Intercell has appointed Staph Leavenworth Bakali as chief business officer. He will have key responsibilities for the …
£600m confirmed for three year Cancer Drugs Fund
October 27, 2010Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing
The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …
Contract research news in brief
October 27, 2010Research and Development Almac, Kinaxo, MediData Solutions, Quintiles, Ricerca Biosciences, Southern Research Institute, Venn Life Sciences, biofocus, contract research
Our latest crop of contract research news includes updates from Quintiles, Venn Life Sciences, Medidata Solutions, Southern Research Institute, Ricerca …
Health outcomes – does anything else matter?
October 27, 2010Research and Development Les Rose, evidence-based medicine, healthcare outcomes, randomised controlled trials
So the mould of British politics has been broken, and we now have a government with probably a broader range …
Pharma engages HTA bodies in early-stage drug discussions
October 27, 2010Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta
Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …
Digital Pharma: UK’s online dementia mentors
October 26, 2010Medical Communications Alzheimer's disease, Comprehensive Spending Review, Digital Pharma blog, dementia, patient education
The Department of Health is looking for hundreds of people to become online dementia mentors as part of it ongoing …
Sanofi moves teriflunomide into phase III MS trials
October 26, 2010Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide
Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …
Hugh Douglas joins BioCision
October 26, 2010Manufacturing and Production BioCision, Hugh Douglas, Lori Kunkel, Paul Nowak, appointment, manufacturing and production
BioCision has expanded its management team, appointing Hugh Douglas as chief operating officer and adding to its corporate advisory board. …
Shared API inspections project gains traction
October 26, 2010Manufacturing and Production API, EDQM, EMA, FDA, TGA, manufacturing compliance, pharma manufacturing, regulatory affairs, regulatory inspections
A three-way initiative between regulatory authorities in the EU, US and Australia on the inspection of facilities making active pharmaceutical …
Pharma manufacturing news in brief
October 26, 2010Manufacturing and Production AMRI, BASF, BMS, Bend Research, Bristol-Myers Squibb, Parmetics, Stirling Pharma, Vical, pharma manufacturing
This week’s round-up of pharmaceutical manufacturing news features updates from Pharmetics, AMRI, Bend Research/BMS, Stirling Pharma, Vical and BASF. A …
Minister confirms NICE will be sidelined in drug evaluation
October 26, 2010Sales and Marketing Andrew Lansley, Lord Howe, NICE, PPRS, medicines pricing, value-based pricing
A health minister has confirmed NICE will be “moved” from its current central role in health technology assessment to make …
Conducting clinical trials in China
October 26, 2010Research and Development China, Jim Wei, Medpace, clinical trials, clinical trials in Chaia, regulatory affairs
As industry pressure to conduct successful global clinical trials on time and on budget continue, tapping emerging global markets will …
Sowing into Good Ground: Using “personalized medicine” for optimal treatment value
October 26, 2010Sales and Marketing Kinapse, White paper
As demonstrating value for the “average patient” becomes ever more difficult, Health Economics and Outcomes Research leaders can use “personalised …
Novartis’ Lucentis recommended for wider EU licence
October 25, 2010Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab
Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …
Kinapse selected by European Medicines Agency to provide EudraVigilance data management services
October 25, 2010Business Services EMA, Kinapse
25 October, 2010 London, UK Kinapse announced today that it has been selected through a European open procurement procedure to …
Arena’s obesity treatment lorcaserin rejected by FDA
October 25, 2010Sales and Marketing Arena Pharma, Eisai, FDA, FDA complete response letter, lorcaserin, obesity
A new weight loss drug has been rejected by the FDA because of numerous concerns about side-effects and limited efficacy. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
